Who are Anti-COVID-19 human immunoglobulin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, batch 1 of Ad5-nCoV, BNT162b7 Monovalent (OMI BA.4/BA.5), BNT162b2 Bivalent (WT/OMI BA.1), Famtozinameran 5 to 11 Years of age, Tozinameran 6 months to 4 years of age.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-covid-19-human-immunoglobulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anti-COVID-19 human immunoglobulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-COVID-19 human immunoglobulin (Anti-COVID-19 human immunoglobulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Infectious Diseases.

phase 2 Monoclonal antibody SARS-CoV-2 spike protein Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

Anti-COVID-19 human immunoglobulin (Anti-COVID-19 human immunoglobulin) — Lifefactors Zona Franca, SAS. Anti-COVID-19 human immunoglobulin works by providing pre-formed antibodies to neutralize the SARS-CoV-2 virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti-COVID-19 human immunoglobulin TARGET	Anti-COVID-19 human immunoglobulin	Lifefactors Zona Franca, SAS	phase 2	Monoclonal antibody	SARS-CoV-2 spike protein
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5)	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age	famtozinameran-5-to-11-years-of-age	Pfizer	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
Tozinameran 6 months to 4 years of age	tozinameran-6-months-to-4-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-COVID-19 human immunoglobulin — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-covid-19-human-immunoglobulin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab